Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Zoulim, Fabien
Fournier, Claire
Habersetzer, Francois
Sprinzl, Martin
Pol, Stanislas
Coffin, Carla S
Vincent, Leroy
Ma, Mang
Wedemeyer, Heiner
Lohse, Ansgar W
Thimme, Robert
Lugardon, Karine
Martin, Perrine
Bastien, Bérangère
Sansas, Benoit
Adda, Nathalie
Halluard, Celine
Bendjama, Kaïdre
Brandely, Maud
Inchauspe, Geneviève

January 2019

Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort ...

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

James S Cavenaugh
Dorka Awi
Maimuna Mendy
Adrian V S Hill
Hilton Whittle
Samuel J McConkey

February 2011

Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safe...

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Zoulim, Fabien
Fournier, Claire
Habersetzer, Francois
Sprinzl, Martin
Pol, Stanislas
Coffin, Carla S
Vincent, Leroy
Ma, Mang
Wedemeyer, Heiner
Lohse, Ansgar W
Thimme, Robert
Lugardon, Karine
Martin, Perrine
Bastien, Bérangère
Sansas, Benoit
Adda, Nathalie
Halluard, Celine
Bendjama, Kaïdre
Brandely, Maud
Inchauspe, Geneviève

January 2020

Funding: TransgèneInternational audienceTreatment of chronic hepatitis B (CHB) typically requires li...

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Lok, Anna S
Pan, Calvin Q
Han, Steven-Huy B
Trinh, Huy N
Fessel, W J
Rodell, Timothy
Massetto, Benedetta
Lin, Lanjia
Gaggar, Anuj
Subramanian, G M
McHutchison, John G
Ferrari, Carlo
Lee, Hannah
Gordon, Stuart C
Gane, Edward J

September 2016

BACKGROUND & AIMS: GS-4774 is a heat-inactivated, yeast-based, T-cell vaccine designed to elicit hep...

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

Gaggar, Anuj
Coeshott, Claire
Apelian, David
Rodell, Timothy
Armstrong, Brian R.
Shen, Gong
Subramanian, G. Mani
McHutchison, John G.

September 2014

AbstractBackgroundGS-4774 is a recombinant, heat-killed, yeast-based immunotherapy engineered to exp...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H.L.A.
Rossi M.
Yoon S.K.
Vecchi A.
Barili V.
Yoshida E.M.
Trinh H.
Rodell T.C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M.R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A.H.
Gaggar A.
Subramanian G.M.
Massetto B.
Fung S.
Ahn S.H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

BACKGROUND & AIMS: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C
Janssen HLA
Rossi M
Yoon SK
Vecchi A
Barili V
Yoshida EM
Trinh H
Rodell TC
Laccabue D
Alfieri A
Brillo F
Fisicaro P
Acerbi G
Pedrazzi G
Andreone P
Cursaro C
Margotti M
Santoro R
Piazzolla V
Brunetto MR
Coco B
Cavallone D1
Zhao Y
Joshi A
Woo J
Lau AH
Gaggar A
Subramanian GM
Massetto B
Fung S
Ahn SH
Ma X
Mangia A
Ferrari C

January 2019

Abstract BACKGROUND & AIMS: One strategy to treat chronic hepatitis B virus (HBV) infection co...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C
Janssen HLA
Rossi M
Yoon SK
Vecchi A
Barili V
Yoshida EM
Trinh H
Rodell TC
Laccabue D
Alfieri A
Brillo F
Fisicaro P
Acerbi G
Pedrazzi G
Andreone P
Cursaro C
Margotti M
Santoro R
Piazzolla V
Brunetto MR
Coco B
Cavallone D1
Zhao Y
Joshi A
Woo J
Lau AH
Gaggar A
Subramanian GM
Massetto B
Fung S
Ahn SH
Ma X
Mangia A
Ferrari C

January 2019

Abstract BACKGROUND & AIMS: One strategy to treat chronic hepatitis B virus (HBV) infection co...

A Whole Recombinant Yeast-Based Therapeutic Vaccine Elicits HBV X, S and Core Specific T Cells in Mice and Activates Human T Cells Recognizing Epitopes Linked to Viral Clearance

Thomas H. King (602303)
Charles B. Kemmler (602304)
Zhimin Guo (602305)
Derrick Mann (602306)
Yingnian Lu (602307)
Claire Coeshott (602308)
Adam J. Gehring (113333)
Antonio Bertoletti (113358)
Zi Z. Ho (602309)
William Delaney (602310)
Anuj Gaggar (602311)
G. Mani Subramanian (602312)
John G. McHutchison (215068)
Shikha Shrivastava (602313)
Yu-Jin L. Lee (602314)
Shyamasundaran Kottilil (424482)
Donald Bellgrau (580348)
Timothy Rodell (602315)
David Apelian (602316)

July 2014

<div><p>Chronic hepatitis B infection (CHB) is characterized by sub-optimal T cell responses to vira...

A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.

Thomas H King
Charles B Kemmler
Zhimin Guo
Derrick Mann
Yingnian Lu
Claire Coeshott
Adam J Gehring
Antonio Bertoletti
Zi Z Ho
William Delaney
Anuj Gaggar
G Mani Subramanian
John G McHutchison
Shikha Shrivastava
Yu-Jin L Lee
Shyamasundaran Kottilil
Donald Bellgrau
Timothy Rodell
David Apelian

Chronic hepatitis B infection (CHB) is characterized by sub-optimal T cell responses to viral antige...

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Zoulim, Fabien
Fournier, Claire
Habersetzer, Francois
Sprinzl, Martin
Pol, Stanislas
Coffin, Carla S
Vincent, Leroy
Ma, Mang
Wedemeyer, Heiner
Lohse, Ansgar W
Thimme, Robert
Lugardon, Karine
Martin, Perrine
Bastien, Bérangère
Sansas, Benoit
Adda, Nathalie
Halluard, Celine
Bendjama, Kaïdre
Brandely, Maud
Inchauspe, Geneviève

January 2019

Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort ...

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

James S Cavenaugh
Dorka Awi
Maimuna Mendy
Adrian V S Hill
Hilton Whittle
Samuel J McConkey

February 2011

Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safe...

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Zoulim, Fabien
Fournier, Claire
Habersetzer, Francois
Sprinzl, Martin
Pol, Stanislas
Coffin, Carla S
Vincent, Leroy
Ma, Mang
Wedemeyer, Heiner
Lohse, Ansgar W
Thimme, Robert
Lugardon, Karine
Martin, Perrine
Bastien, Bérangère
Sansas, Benoit
Adda, Nathalie
Halluard, Celine
Bendjama, Kaïdre
Brandely, Maud
Inchauspe, Geneviève

January 2020

Funding: TransgèneInternational audienceTreatment of chronic hepatitis B (CHB) typically requires li...

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Lok, Anna S
Pan, Calvin Q
Han, Steven-Huy B
Trinh, Huy N
Fessel, W J
Rodell, Timothy
Massetto, Benedetta
Lin, Lanjia
Gaggar, Anuj
Subramanian, G M
McHutchison, John G
Ferrari, Carlo
Lee, Hannah
Gordon, Stuart C
Gane, Edward J

September 2016

BACKGROUND & AIMS: GS-4774 is a heat-inactivated, yeast-based, T-cell vaccine designed to elicit hep...

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

Gaggar, Anuj
Coeshott, Claire
Apelian, David
Rodell, Timothy
Armstrong, Brian R.
Shen, Gong
Subramanian, G. Mani
McHutchison, John G.

September 2014

AbstractBackgroundGS-4774 is a recombinant, heat-killed, yeast-based immunotherapy engineered to exp...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H.L.A.
Rossi M.
Yoon S.K.
Vecchi A.
Barili V.
Yoshida E.M.
Trinh H.
Rodell T.C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M.R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A.H.
Gaggar A.
Subramanian G.M.
Massetto B.
Fung S.
Ahn S.H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

Background & Aims: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Boni C.
Janssen H. L. A.
Rossi M.
Yoon S. K.
Vecchi A.
Barili V.
Yoshida E. M.
Trinh H.
Rodell T. C.
Laccabue D.
Alfieri A.
Brillo F.
Fisicaro P.
Acerbi G.
Pedrazzi G.
Andreone P.
Cursaro C.
Margotti M.
Santoro R.
Piazzolla V.
Brunetto M. R.
Coco B.
Cavallone D.
Zhao Y.
Joshi A.
Woo J.
Lau A. H.
Gaggar A.
Subramanian G. M.
Massetto B.
Fung S.
Ahn S. H.
Ma X.
Mangia A.
Ferrari C.

January 2019

BACKGROUND & AIMS: One strategy to treat chronic hepatitis B virus (HBV) infection could be to i...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C
Janssen HLA
Rossi M
Yoon SK
Vecchi A
Barili V
Yoshida EM
Trinh H
Rodell TC
Laccabue D
Alfieri A
Brillo F
Fisicaro P
Acerbi G
Pedrazzi G
Andreone P
Cursaro C
Margotti M
Santoro R
Piazzolla V
Brunetto MR
Coco B
Cavallone D1
Zhao Y
Joshi A
Woo J
Lau AH
Gaggar A
Subramanian GM
Massetto B
Fung S
Ahn SH
Ma X
Mangia A
Ferrari C

January 2019

Abstract BACKGROUND & AIMS: One strategy to treat chronic hepatitis B virus (HBV) infection co...

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C
Janssen HLA
Rossi M
Yoon SK
Vecchi A
Barili V
Yoshida EM
Trinh H
Rodell TC
Laccabue D
Alfieri A
Brillo F
Fisicaro P
Acerbi G
Pedrazzi G
Andreone P
Cursaro C
Margotti M
Santoro R
Piazzolla V
Brunetto MR
Coco B
Cavallone D1
Zhao Y
Joshi A
Woo J
Lau AH
Gaggar A
Subramanian GM
Massetto B
Fung S
Ahn SH
Ma X
Mangia A
Ferrari C

January 2019

Abstract BACKGROUND & AIMS: One strategy to treat chronic hepatitis B virus (HBV) infection co...

A Whole Recombinant Yeast-Based Therapeutic Vaccine Elicits HBV X, S and Core Specific T Cells in Mice and Activates Human T Cells Recognizing Epitopes Linked to Viral Clearance

Thomas H. King (602303)
Charles B. Kemmler (602304)
Zhimin Guo (602305)
Derrick Mann (602306)
Yingnian Lu (602307)
Claire Coeshott (602308)
Adam J. Gehring (113333)
Antonio Bertoletti (113358)
Zi Z. Ho (602309)
William Delaney (602310)
Anuj Gaggar (602311)
G. Mani Subramanian (602312)
John G. McHutchison (215068)
Shikha Shrivastava (602313)
Yu-Jin L. Lee (602314)
Shyamasundaran Kottilil (424482)
Donald Bellgrau (580348)
Timothy Rodell (602315)
David Apelian (602316)

July 2014

<div><p>Chronic hepatitis B infection (CHB) is characterized by sub-optimal T cell responses to vira...

A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.

Thomas H King
Charles B Kemmler
Zhimin Guo
Derrick Mann
Yingnian Lu
Claire Coeshott
Adam J Gehring
Antonio Bertoletti
Zi Z Ho
William Delaney
Anuj Gaggar
G Mani Subramanian
John G McHutchison
Shikha Shrivastava
Yu-Jin L Lee
Shyamasundaran Kottilil
Donald Bellgrau
Timothy Rodell
David Apelian

Chronic hepatitis B infection (CHB) is characterized by sub-optimal T cell responses to viral antige...

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Zoulim, Fabien
Fournier, Claire
Habersetzer, Francois
Sprinzl, Martin
Pol, Stanislas
Coffin, Carla S
Vincent, Leroy
Ma, Mang
Wedemeyer, Heiner
Lohse, Ansgar W
Thimme, Robert
Lugardon, Karine
Martin, Perrine
Bastien, Bérangère
Sansas, Benoit
Adda, Nathalie
Halluard, Celine
Bendjama, Kaïdre
Brandely, Maud
Inchauspe, Geneviève

January 2019

Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort ...

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

James S Cavenaugh
Dorka Awi
Maimuna Mendy
Adrian V S Hill
Hilton Whittle
Samuel J McConkey

February 2011

Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safe...

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Zoulim, Fabien
Fournier, Claire
Habersetzer, Francois
Sprinzl, Martin
Pol, Stanislas
Coffin, Carla S
Vincent, Leroy
Ma, Mang
Wedemeyer, Heiner
Lohse, Ansgar W
Thimme, Robert
Lugardon, Karine
Martin, Perrine
Bastien, Bérangère
Sansas, Benoit
Adda, Nathalie
Halluard, Celine
Bendjama, Kaïdre
Brandely, Maud
Inchauspe, Geneviève

January 2020

Funding: TransgèneInternational audienceTreatment of chronic hepatitis B (CHB) typically requires li...

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Abstract

Extracted data

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Abstract

Extracted data

Related items

Related items